论文部分内容阅读
目的:研究两种剂量的肺表面活性物质联合鼻塞持续正压通气(nCPAP)治疗新生儿呼吸窘迫综合征(RDS)的临床疗效。方法:将2009年1月至2012年1月我院新生儿科收治的64例RDS患儿随机分为观察组和对照组各32例,两组均给予nCPAP进行治疗,并且观察组给予肺表面活性物质100 mg/kg气管内给药,对照组给予肺表面活性物质200 mg/kg气管内给药,比较两种治疗方法的临床疗效。结果:两组患儿在机械通气率、脑室内出血率及辅助通气时间、吸氧时间、住院天数等方面比较差异均无统计学意义(P>0.05),两组患儿72 h内PaO2、PaCO2、a/APO2、PaO2/FiO2等指标比较差异均无统计学意义(P>0.05)。结论:肺表面活性物质100 mg/kg和200 mg/kg联合nCPAP治疗RDS均能改善患儿的临床症状,减少并发症及死亡的发生,并且两种剂量的疗效差异无统计学意义。
Objective: To study the clinical efficacy of two doses of pulmonary surfactant plus nasal continuous positive airway pressure (nCPAP) in the treatment of neonatal respiratory distress syndrome (RDS). Methods: Sixty-four patients with RDS admitted to neonatology department of our hospital from January 2009 to January 2012 were randomly divided into observation group (32 cases) and control group (32 cases). Both groups were treated with nCPAP, and the observation group was given pulmonary surfactant The substance was administered intratracheally at 100 mg / kg and the control group was administered intratracheally with 200 mg / kg of pulmonary surfactant. The clinical efficacy of the two treatments was compared. Results: There was no significant difference between the two groups in the mechanical ventilation rate, the rate of intraventricular hemorrhage, the time of assisted ventilation, the time of oxygen inhalation and the length of hospital stay (P> 0.05). PaO2, PaCO2 , A / APO2, PaO2 / FiO2 and other indicators showed no significant difference (P> 0.05). CONCLUSIONS: Both pulmonary surfactant 100 mg / kg and nCPAP 200 mg / kg in combination with RCP can improve the clinical symptoms, reduce complications and death in children, and there is no significant difference between the two doses.